Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting

详细信息    查看全文

• 作者：Sunil A. Reddy ^{sreddy@stanford.edu" class="auth_mail" title="E-mail the corresponding author}Author Vitae
• 关键词：Cutaneous T-cell lymphoma ; Romidepsin ; Histone deacetylase inhibitor
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：106
• 期：Complete
• 页码：99-107
• 全文大小：733 K

文摘

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of rare non-Hodgkin lymphomas that arise in the skin. In advanced stages, CTCL becomes systemic and is associated with poor prognosis. Diagnosis of CTCL and treatment of early-stage disease with topical therapies often occurs under the care of a dermatologist. Community oncologists see few patients with CTCL due to direct referrals from dermatologists to academic or lymphoma specialty centers. However, some patients will continue to be managed in a community setting. Currently there is no evidence-based stepwise algorithm for treatment of patients with CTCL, and guidelines suggest a wide range of systemic therapies, including biologics, targeted agents, and more traditional chemotherapies. To provide optimal care in a community setting, oncologists must become familiar with newer nonchemotherapeutic treatment options. This review highlights romidepsin, a histone deacetylase inhibitor approved for the treatment of patients with CTCL who have received ≥1 prior systemic therapy.